Peter J K van Meer
Overview
Explore the profile of Peter J K van Meer including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
17
Citations
204
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Chien H, Roos P, Russel F, Theunissen P, van Meer P
Regul Toxicol Pharmacol
. 2024 Aug;
152:105682.
PMID: 39094967
Regulatory guidance for global drug development relies on animal studies to evaluate safety risks for humans, including risk of reproductive toxicity. Weight-of-evidence approaches (WoE) are increasingly becoming acceptable to evaluate...
2.
Roos P, Anggasta C, Piersma A, van Meer P, Theunissen P
Crit Rev Toxicol
. 2024 Aug;
54(9):619-633.
PMID: 39093553
Embryofetal development (EFD) studies are performed to characterize risk of drugs in pregnant women and on embryofetal development. In line with the ICH S5(R3) guideline, these studies are generally conducted...
3.
Ferreira G, Dijkstra F, Veening-Griffioen D, Boon W, Schellekens H, Moors E, et al.
Transl Psychiatry
. 2023 Mar;
13(1):74.
PMID: 36859342
The primary purpose of this study was to assess the translatability of preclinical to early clinical tolerable and pharmacologically active dose ranges for central nervous system (CNS) active drugs. As...
4.
Dekker M, de Vries S, Versantvoort C, Drost-van Velze E, Bhatt M, van Meer P, et al.
Front Med (Lausanne)
. 2021 Apr;
8:643028.
PMID: 33791329
This study assessed to what extent women were included in all phases of drug development; whether the clinical studies in the marketing authorization application dossiers include information per sex; and...
5.
Ferreira G, Veening-Griffioen D, Boon W, Moors E, van Meer P
Animals (Basel)
. 2020 Jul;
10(7).
PMID: 32679706
Reports of a reproducibility crisis combined with a high attrition rate in the pharmaceutical industry have put animal research increasingly under scrutiny in the past decade. Many researchers and the...
6.
Tradition, not science, is the basis of animal model selection in translational and applied research
Veening-Griffioen D, Ferreira G, Boon W, Gispen-de Wied C, Schellekens H, Moors E, et al.
ALTEX
. 2020 Jun;
38(1):49-62.
PMID: 32591838
National and international laws and regulations exist to protect animals used for scientific purposes in translational and applied research, which includes drug development. However, multiple animal models are available for...
7.
Ferreira G, Veening-Griffioen D, Boon W, Hooijmans C, Moors E, Schellekens H, et al.
Eur J Pharmacol
. 2020 May;
879:173153.
PMID: 32360835
Previous qualitative research has suggested there are only minor differences between the db/db mouse and the Zucker Diabetic Fatty (ZDF) rat, both animal models of type 2 diabetes. However, it...
8.
Ferreira G, Veening-Griffioen D, Boon W, Moors E, Gispen-de Wied C, Schellekens H, et al.
PLoS One
. 2019 Jul;
14(7):e0220325.
PMID: 31329650
[This corrects the article DOI: 10.1371/journal.pone.0218014.].
9.
Veening-Griffioen D, Ferreira G, van Meer P, Boon W, Gispen-de Wied C, Moors E, et al.
Eur J Pharmacol
. 2019 Jul;
859:172524.
PMID: 31291566
Clinical trial failures (>99%) in Alzheimer's disease are in stark contrast to positive efficacy data in animals. We evaluated the correlation between animal and clinical efficacy outcomes (cognition) in Alzheimer's...
10.
Ferreira G, Veening-Griffioen D, Boon W, Moors E, Gispen-de Wied C, Schellekens H, et al.
PLoS One
. 2019 Jun;
14(6):e0218014.
PMID: 31194784
Introduction: Poor translation of efficacy data derived from animal models can lead to clinical trials unlikely to benefit patients-or even put them at risk-and is a potential contributor to costly...